{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:24:44Z","timestamp":1778077484198,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,8,3]],"date-time":"2013-08-03T00:00:00Z","timestamp":1375488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s00280-013-2244-4","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T06:52:38Z","timestamp":1375426358000},"page":"917-923","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas"],"prefix":"10.1007","volume":"72","author":[{"given":"Shivaani","family":"Kummar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence W.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Raymond W.","family":"Klecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Murgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry M.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,3]]},"reference":[{"key":"2244_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/BF00175391","volume":"6","author":"J Plowman","year":"1988","unstructured":"Plowman J, Paull KD, Atassi G, Harrison SD Jr, Dykes DJ, Kabbe HJ, Narayanan VL, Yoder OC (1988) Preclinical antitumor activity of batracylin (NSC 320846). Invest New Drugs 6:147\u2013153","journal-title":"Invest New Drugs"},{"key":"2244_CR2","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/BF00685160","volume":"27","author":"WR Waud","year":"1991","unstructured":"Waud WR, Harrison SD Jr, Gilbert KS, Laster WR Jr, Griswold DP Jr (1991) Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother Pharmacol 27:456\u2013463","journal-title":"Cancer Chemother Pharmacol"},{"key":"2244_CR3","doi-asserted-by":"publisher","first-page":"9971","DOI":"10.1158\/0008-5472.CAN-07-0804","volume":"67","author":"VA Rao","year":"2007","unstructured":"Rao VA, Agama K, Holbeck S, Pommier Y (2007) Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone gamma-H2AX as a biomarker of DNA damage. Cancer Res 67:9971\u20139979","journal-title":"Cancer Res"},{"key":"2244_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF00173759","volume":"7","author":"P Mucci-LoRusso","year":"1989","unstructured":"Mucci-LoRusso P, Polin L, Bissery MC, Valeriote F, Plowman J, Luk GD, Corbett TH (1989) Activity of batracylin (NSC-320846) against solid tumors of mice. Invest New Drugs 7:295\u2013306","journal-title":"Invest New Drugs"},{"key":"2244_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00176974","volume":"9","author":"MM Ames","year":"1991","unstructured":"Ames MM, Mathiesen DA, Reid JM (1991) Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat. Invest New Drugs 9:219\u2013225","journal-title":"Invest New Drugs"},{"key":"2244_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1023\/A:1007692503817","volume":"16","author":"GJ Stevens","year":"2000","unstructured":"Stevens GJ, Burkey JL, McQueen CA (2000) Toxicity of the heterocyclic amine batracylin: investigation of rodent N-acetyltransferase activity and potential contribution of cytochrome P450 3A. Cell Biol Toxicol 16:31\u201339","journal-title":"Cell Biol Toxicol"},{"key":"2244_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0006-2952(97)00140-8","volume":"54","author":"LA Trepanier","year":"1997","unstructured":"Trepanier LA, Ray K, Winand NJ, Spielberg SP, Cribb AE (1997) Cytosolic arylamine n-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem Pharmacol 54:73\u201380","journal-title":"Biochem Pharmacol"},{"key":"2244_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1006\/abio.1995.9978","volume":"231","author":"MA Doll","year":"1995","unstructured":"Doll MA, Fretland AJ, Deitz AC, Hein DW (1995) Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal Biochem 231:413\u2013420","journal-title":"Anal Biochem"},{"key":"2244_CR9","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","volume":"89","author":"R Simon","year":"1997","unstructured":"Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138\u20131147","journal-title":"J Natl Cancer Inst"},{"key":"2244_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"2244_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/03602530902843483","volume":"41","author":"S-F Zhou","year":"2009","unstructured":"Zhou S-F, Liu J-P, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89\u2013295","journal-title":"Drug Metab Rev"},{"key":"2244_CR12","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","volume":"22","author":"F Innocenti","year":"2004","unstructured":"Innocenti F, Undevia SD, Iyer L, Xian Chen P, Das S, Kocherginsky M, Karrison T, Janisch L, Ram\u00edrez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan. J Clin Oncol 22:1382\u20131388","journal-title":"J Clin Oncol"},{"key":"2244_CR13","first-page":"853","volume":"82","author":"D Evans","year":"1960","unstructured":"Evans D, Storey P, Wittstadt F, Manley K (1960) The determination of the isoniazid inactivator phenotype. Am Rev Respir Dis 82:853\u2013861","journal-title":"Am Rev Respir Dis"},{"key":"2244_CR14","first-page":"2304","volume":"53","author":"MJ Ratain","year":"1993","unstructured":"Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB (1993) Phase I Study of Amonafide Dosing Based on Acetylator Phenotype. Cancer Res 53:2304\u20132308","journal-title":"Cancer Res"},{"key":"2244_CR15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1136\/jmg.34.9.758","volume":"34","author":"C Smith","year":"1997","unstructured":"Smith C, Wadelius M, Gough A, Harrison D, Wolf C, Rane A (1997) A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 34:758\u2013760","journal-title":"J Med Genet"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2244-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2244-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2244-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2244-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T01:30:44Z","timestamp":1581989444000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2244-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,3]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["2244"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2244-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,3]]}}}